A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

The main aim of this study is to evaluate the pharmacokinetic (PK) comparability between TAK-881 and HYQVIA subcutaneous (SC) administration for maintenance therapy of CIDP. The participants who are already receiving intravenous immunoglobulin G (IGIV), conventional subcutaneous intravenous immunoglobulin G (cIGSC), or HYQVIA will be treated with the same dose equivalent as their prior IG treatment with HYQVIA for 20 weeks followed by TAK-881 for 24 weeks. Participants will need to visit the clinic every 3 or 4 weeks until they enter the extension phase. In the extension phase, home infusions are allowed, and visits will occur between every 12 weeks and 24 weeks.

NCT Number	NCT06747351
Lead Sponsor	Takeda Collaborators: Takeda Development Center Americas, Inc.
Conditions	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Enrollment	59 participants
Start Date	2025-05-06
Primary Completion	2028-06-25 (estimated)
Study Completion	2028-06-25 (estimated)
Updated on ClinicalTrials.gov	2026-01-20